Renal cell carcinoma (RCC) accounts for 2–3% of all malignant disease in adults, with 30%
of RCC diagnosed at locally advanced or metastatic stages of disease. A form of locally …

Renal cell carcinoma (RCC) is the third most common genitourinary cancer accounting for
approximately 180,000 deaths worldwide in 2020. Although over two-thirds of patients …

Perioperative immune checkpoint inhibitor (ICI) trials for intermediate high-risk clear cell
renal cell carcinoma (ccRCC) have failed to consistently demonstrate improved patient …

Background Further stratification of the risk of recurrence of clear-cell renal cell carcinoma
(ccRCC) with venous tumor thrombus (VTT) will facilitate selection of candidates for adjuvant …

Objective: Renal clear cell carcinoma (ccRCC) is the most common type of renal cancer.
Here we aim to explore the prognosis and immunotherapeutic value of copper death-related …

Across a multitude of cancers, extirpative surgery is the cornerstone of treatment for patients
with localized and locally advanced disease. However, a portion of these patients …

Background Clear cell renal cell carcinoma (ccRCC) is a common urinary cancer. Although
diagnostic and therapeutic approaches for ccRCC have been improved, the survival …

PURPOSE Targeted tyrosine kinase inhibitors (TKIs) and immune-checkpoint inhibitors
(ICIs) revolutionized the treatment of metastatic renal cell carcinoma (RCC). Efforts to …

Adjuvant therapy in renal cell carcinoma after surgery has been investigated in numerous
clinical trials since the 1990s. However, only two trials have shown an improved disease …

Immune checkpoint blockade therapy represented by programmed cell death ligand 1 (PD-
L1) inhibitor for advanced renal carcinoma with an objective response rate (ORR) in patients …